Speakers:

Andrew Forman, Managing Director, Senior Analyst, Specialty Pharmaceuticals at WR Hambrecht + Co. and ranked last year by Forbes and in a Wall Street Journal survey as the No. 1 pharmaceutical analyst, served as the keynote speaker.

Caren Franzini, Chief Executive Officer of the New Jersey Economic Development Authority (EDA), spoke on how biotechnology companies can benefit from the new Edison Innovation Fund.

Discussion Panel: Targeted Therapies: Who Will Pay? Sponsored by the Deloitte Center for Health Solutions

The evolution and transformation in the life sciences and health care industry is advancing at breakneck speed. However, the science of personalized medicine is rapidly outpacing the economics. The panel reviewed the rapidly evolving field of personalized medicine from the perspective of those stakeholders who are responsible for driving or limiting its adoption, implementation, and use over the next several years and decades. It also addressed the need for significant collaboration among these stakeholders as a prerequisite for overcoming challenges and realizing the full promise of targeted therapies.

Panel Members:
Christine Côté, M.D., Johnson & Johnson Inc.
Naim Munir, M.D., Horizon Blue Cross Blue Shield of New Jersey
Steven Herman, Ph.D., Roche Molecular Systems, Inc.
Matthew Hudes, Deloitte Consulting LLP
R.T. (Terry) Hisey, Deloitte Consulting LLP - Moderator

Program:
5:00-6:00 PM - Reception Networking, Exhibits
6:00-6:15 PM - Welcome, Introductions and Awards
6:15-6:45 PM - Keynote Address
6:45-7:45 PM - Panel Discussion

Location:
The Friend Center for Engineering Education
Princeton University
William and Olden Streets
Princeton, New Jersey
(Click here for directions.)